Company profile: Antabio
1.1 - Company Overview
Company description
- Provider of novel antibacterial resistance-breakers for drug-resistant infections, developing stand-alone inhibitors of bacterial metalloenzymes to restore antibiotic activity against critical pathogens; products include MEM-ANT3310 (meropenem + ANT3310, a serine-beta-lactamase inhibitor; targets CRAB and CRE), ANT3273 (inhaled for Pseudomonas aeruginosa), and ANT2681 (metallo β-lactamase inhibitor + meropenem for NDM CRE).
Products and services
- ANT2681: An intravenous metallo β-lactamase inhibitor combined with meropenem, engineered to treat NDM-carrying carbapenem-resistant Enterobacteriaceae in drug-resistant infections
- ANT3273: A nebuliser-administered inhaled treatment engineered to target Pseudomonas aeruginosa infections in chronic respiratory diseases via inhalation therapy delivered by nebuliser
- MEM-ANT3310: A combination-therapy pairing carbapenem meropenem with ANT3310, a serine-beta-lactamase inhibitor, to target drug-resistant pathogens including CRAB and CRE
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Antabio
Arbutus Biopharma
HQ: Canada
Website
- Description: Provider of biopharmaceutical therapies for hepatitis B virus (HBV), including Imdusiran (AB-729), a subcutaneously delivered RNAi therapeutic designed to reduce HBV viral antigens such as HBsAg, and AB-101, an oral PD-L1 inhibitor intended to reawaken HBV-specific T cells by blocking the PD-1/PD-L1 protein-protein interaction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arbutus Biopharma company profile →
Cytovale
HQ: United States
Website
- Description: Provider of early detection diagnostic technologies for immune-mediated diseases, including the IntelliSep Test for rapid sepsis identification with results in under 10 minutes to aid emergency department triage, powered by microfluidics, precision imaging, and machine learning to analyze complex biological data and perform detailed cellular analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cytovale company profile →
Scynexis
HQ: United States
Website
- Description: Provider of drug discovery, development and manufacturing projects focused on antifungal therapeutics, including ibrexafungerp, a novel oral/IV glucan synthase inhibitor for serious and resistant fungal infections; SCY-247, a second-generation broad-spectrum triterpenoid; VVC and RVVC treatments; and the MARIO study evaluating oral step-down after IV echinocandin for invasive candidiasis and candidemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scynexis company profile →
Resistell
HQ: Switzerland
Website
- Description: Provider of antibiotic resistance testing via Phenotech Multistar, an ultra-rapid Antibiotic Susceptibility Testing (AST) platform using nanomotion technology to deliver results in 2 hours independent of bacterial growth, and Phenotech Research, a research device measuring nanoscale cellular vibrations to study growth phenotypes and provide rapid test results.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Resistell company profile →
Elion Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology solutions focused on treating life-threatening IFIs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elion Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Antabio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Antabio
2.2 - Growth funds investing in similar companies to Antabio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Antabio
4.2 - Public trading comparable groups for Antabio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →